June 8 Quick Takes: FDA approves Prevnar 20; plus Bayer’s BlueRock, Innovent-IASO, Strateos, Aclaris, Incyte and more

CDC’s Advisory Committee on Immunization Practices (ACIP) will meet in October to discuss and update recommendations on adult immunizations with pneumococcal vaccines including Prevnar 20 from Pfizer Inc. (NYSE:PFE) after its approval late Tuesday. According to the company, it’s the first approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia in the U.S.

Bayer AG (Xetra:BAYN) subsidiary BlueRock Therapeutics L.P. has begun dosing Parkinson’s disease patients in a Phase I trial of DA01, marking the start of the first human trial of a product comprising induced pluripotent stem (iPS) stem cell-derived dopaminergic neurons to treat the neurodegenerative disorder. The pharma acquired BlueRock in 2019 for $240 million in cash up front and up to $360 million in milestones...